Renal Business Today - Biotrends Research

Bundle Tightens ESA Use Among Nephrologists

EXTON, Pa.—The dialysis bundle has caused nephrologists to increase the use of iron, increase the use of subcutaneous ESA administration, and lower erythropoeitin-stimulating agent (ESA) dosing by tightening hemoglobin target levels, according to new survey results from ...More

July 11, 2011

Posted in News, Clinical & Pharma, Government & Regulation

Report Finds Unmet Need in Acute Kidney Injury

EXTON, Pa.— Relative to a number of other conditions in nephrology, acute kidney injury (AKI), previously termed acute renal failure, is considered to be one of the areas of greatest need, according to a recent report from BioTrends. ...More

June 7, 2011

Posted in News, Clinical & Pharma, Practice Management

Bundle Affects Secondary Hyperparathyroidism Treatment

EXTON, Pa.—The new dialysis bundled payment system has started to change a number of key areas in the management of secondary hyperparathyroidism in the dialysis setting, seemingly in an effort to save costs, according to a new report from BioTrends Research Group. ...More

May 26, 2011

Posted in News, Business, Clinical & Pharma, Government & Regulation

Dialysis Bundle Changes ESA, IV Iron Use

EXTON, Pa.—Nephrologists have reported changes in the use of erythropoietin stimulating agents (ESAs) and intravenous (IV) iron in the management of renal anemia in dialysis patients due to the new dialysis bundled payment system, according to a new report from BioTrends ...More

May 2, 2011

Posted in News, Clinical & Pharma, Practice Management

Survey: Bundle's Biggest Impact on Anemia Management

EXTON, Pa.—Nephrologists say that the new dialysis bundled payment has had the greatest impact on renal anemia management, according to a new report from BioTrends. ...More

April 12, 2011

Posted in News, Clinical & Pharma, Practice Management

Discrepancies in Phosphorus Binder Initiation

EXTON, Pa.— There is a significant discrepancy between the phosphorus level at which nephrologists report initiating phosphate binders in non-dialysis kidney disease patients compared to what actually happens based on audited chart figures, according to a new report from ...More

November 29, 2010

Posted in News, Clinical & Pharma

Use of Anemia Drugs in CKD Stabilizing

EXTON, Pa.— The use of erythropoietin-stimulating agents (ESAs) in patients with chronic kidney disease not on dialysis (CKD-ND) is showing signs of stabilization, according to the latest survey released by BioTrends Research. ...More

October 27, 2010

Posted in News, Clinical & Pharma, Practice Management

Early CKD Diagnosis on Rise in China

EXTON, Pa.—In China, earlier diagnosis of renal insufficiency is leading to a rapid increase in the number of patients being seen by nephrologists; however, there were numerous mentions about the disparity of care across regions, according to a new survey released by ...More

October 6, 2010

Posted in News, Clinical & Pharma, Practice Management

Survey: Anemia Managers Targeting Lower Hemoglobin

EXTON, Pa.— In the dialysis and chronic kidney disease non-dialysis (CKD-ND) settings, holding erythropoiesis-stimulating agents (ESAs) at lower hemoglobin levels and lower hemoglobin targets are the most common recent changes reported by anemia managers, according to a new ...More

September 28, 2010

Posted in News, Practice Management

More Non-Nephrologists Using CKD Guidelines

EXTON, Pa.—There has been a substantial increase in the last two years in awareness and use of the National Kidney Foundation chronic kidney disease staging criteria among non-nephrologists, according to study results released Sept. 8 by BioTrends Research. ...More

September 8, 2010

Posted in News, Practice Management

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Biotrends Research

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail